Abstract:Community-acquired pneumonia (CAP) remains a common and serious illness with approximately 2-4 million cases reported annually. Management of CAP is therapeutically challenging due to the increasing prevalence of penicillin- and macrolide-resistant pneumococci and beta-lactamase producing Haemophilus influenzae, as well as the increased recognition of 'atypical' pathogens, such as Chlamydia pneumoniae and Mycoplasma pneumoniae, and the frequent need for empiric therapy. We aimed to evaluate the safety and efficacy of moxifloxacin in the treatment of patients with CAP. To do this we carried out a prospective, uncontrolled, non-blind, Phase III clinical trial, in 27 U.S. centers. Patients included in the study were over 18 years of age with signs and symptoms of CAP confirmed by evidence of a new or progressive infiltrate on chest radiograph. The intervention used was moxifloxacin 400 mg PO once daily for 10 days. Sputum samples were collected pretherapy for Gram stain and culture for typical organisms. Culture and serological testing for Chlamydia pneumoniae and Mycoplasma pneumoniae was also performed. Susceptibility to moxifloxacin was determined by disk diffusion and MIC. Clinical and bacteriological responses were determined at the end of therapy (0-6 days post-therapy), follow-up (14-35 days post-therapy) and overall (end of therapy plus follow-up). Analyses were performed on both valid for efficacy and intent-to-treat populations. The primary efficacy variable was overall clinical resolution. Of 254 patients enrolled in the Study, 196 patients were included in the efficacy analyses. The majority of patients were male (58%) and Caucasian (85%) with a mean age of 49 years (range: 18 to 85 years). Only 3% of patients were hospitalized pretherapy. The most common pretherapy organisms identified, by culture or serology, in the valid for efficacy population (i.e. 147 organisms among 116 patients), were: Chlamydia pneumoniae (n=63; 54%), Mycoplasma pneumoniae (n=29; 25%), Streptococcus pneumoniae (n=14; 12%) and Haemophilus influenzae (n=13; 10%). End of therapy, follow-up and overall clinical resolution rates for the valid for efficacy population were 94%, 93% and 93%, respectively. The 95% CI for the overall clinical resolution rate was 88.1%, 95.9%. The overall bacteriological response for patients diagnosed by culture or serological criteria, was 91% (95% CI=84%, 96%). For patients who only met serological criteria for infection, the overall bacteriological response was 94% (60/64). Bacterial response rates for the four most commonly isolated pathogens were: 89% (56/63) for C. pneumoniae, 93% (27/29) for M. pneumoniae, 93% (13/14) for S. pneumoniae and 85% (11/13) for H. influenzae. Drug-related adverse events were reported in 33% (85/254) of moxifloxacin-treated patients. Nausea (9%), diarrhea (6%) and dizziness (4%) were the most commonly reported adverse events. Atypical organisms were isolated in high frequency among patients with CAP. Moxifloxacin 400 mg once daily for 10 days was effective and well-tolerated in the treatment of these adult patients with CAP. Moxifloxacin offers an effective treatment alternative for CAP due to both typical and atypical bacterial pathogens.

Sequential moxifloxacin therapy in hospitalized patients with community-acquired pneumonia

A Randomized, Controlled, Multicenter Clinical Trial To Evaluate The Efficacy And Safety Of Oral Sitafloxacin Versus Moxifloxacin In Adult Patients With Community-Acquired Pneumonia

Randomized Controlled Clinical Trial of Moxifloxacin Versus Levofloxacin Injection in the Treatment of Community Acquired Pneumonia

Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group

Clinical study of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia

A multi-centric randomized controlled trial of sequential intravenous moxifloxacin in comparison to cefoperazone-sulbactam for the treatment of acute biliary tract infection

Moxifloxacin monotherapy versus combination therapy in patients with severe community-acquired pneumonia evoked ARDS

A Multicentre, Randomised, Double-Blind, Double-Dummy, Parallel-Controlled, Phase 3 Clinical Trial Assessing the Efficacy and Safety of Intravenous Nemonoxacin Malate Versus Levofloxacin for Community-Acquired Pneumonia in Adult Patients

Clinical evaluation on the empirical treatment of community acquired pneumonia

A randomized, open, multicenter clinical study on the short course of intravenous infusion of 750 mg of levofloxacin and the sequential standard course of intravenous infusion/oral administration of 500 mg of levofloxacin for treatment of community-acquired pneumonia

Moxifloxacin in Treatment of Malignant Tumor Merged Hospital-Acquired Pneumonia:Observation on Its Curative Effect

Comprehensive clinical evaluation of moxifloxacin: A retrospective study

Intravenous Moxifloxacin in Routine Hospital Treatment of Respiratory Tract Infections in China: Results of a Multicenter, Noninterventional Study.

A Randomized, Double-Blind, Multicenter Phase II Study Comparing the Efficacy and Safety of Oral Nemonoxacin with Oral Levofloxacin in the Treatment of Community-Acquired Pneumonia

Clinical evaluation of azithromycin sequential therapy in the treatment of 138 patients with community-acquired pneumonia

Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial

A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia

Study on the efficacy and safety in uncomplicated pelvic inflammatory disease

A randomized controlled clinical trial of levofloxacin 750 mg versus 500 mg intravenous infusion in the treatment of community-acquired pneumonia

Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis and COPD: a systematic review and meta-analysis.

Safety study of moxifloxacin in children with severe refractory Mycoplasma pneumoniae pneumonia